ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflutinib

Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.

Drug pageAflutinib: every studyMany companies study it; this page follows only the 21 they lead. All 63 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Apr 12, 202121 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allist Pharmaceuticals114 open or runningphase 3since Apr 12, 2021Nov 21, 2016Dec 2026phase 3 · NCT04853342
Beijing Aosaikang Pharmaceuticalits history only41 open or runningphase 3since Oct 12, 2019Apr 10, 2018none ahead
ArriVent BioPharmaits history only33 open or runningphase 3since Oct 31, 2022Apr 6, 2022Feb 2029phase 3 · NCT07185997
Abbisko Caymanits history only11 open or runningphase 2since Oct 30, 2024Oct 30, 2024Dec 30, 2027phase 2 · NCT06668103
Alphamab Oncologyits history only11 open or runningphase 1since Mar 5, 2025Mar 5, 2025Jun 30, 2028phase 1 · NCT06868732
MediLink Therapeutics (Suzhou)its history only11 open or runningphase 2since Sep 3, 2025Sep 3, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 21, 2016First study: phase 1 study in NSCLCFirst studyNCT02973763 · 14 enrolled
  2. Apr 18, 2017No phase study in Advanced NSCLCNCT03127449 · 116 enrolled · China
  3. Feb 26, 2018Phase 2 study in Advanced NSCLC Patients With T790MNCT03452592 · 220 enrolled · China
  4. Apr 23, 20192 phase 1 studies in Healthy Male VolunteersNCT03926182, NCT03941340
  5. Apr 12, 2021Phase 1 study in NSCLCNCT04858958 · 90 enrolled · China
  6. Apr 12, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04853342 · 318 planned · China
  7. Jul 5, 2021Phase 1 study in NSCLCNCT04958967 · China
  8. Jul 14, 2022Phase 2 study in NSCLCNCT05466149 · 100 enrolled · China
  9. Apr 9, 2025Phase 3 study in NSCLC Patients With Brain MetastasisNCT06970639 · 380 planned · China
  10. May 20, 2025Phase 3 study in NSCLCNCT07010419 · 338 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT04853342
  2. Oct 31, 2028Primary completion: phase 3 study in NSCLCNCT07010419
  3. Mar 2029Primary completion: phase 3 study in NSCLC Patients With Brain MetastasisNCT06970639

TargetBeta

EGFR →read by rule
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 11 Allist Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07010419NSCLC · China3RecruitingOct 31, 2028338
NCT06970639NSCLC Patients With Brain Metastasis · China3RecruitingMar 2029380
NCT05466149NSCLC · China2Active, not recruitingJun 27, 2025100
NCT04958967NSCLC · China1WithdrawnMay 1, 20220
NCT04858958NSCLC · China1CompletedDec 5, 202490
NCT04853342Carcinoma, Non-Small-Cell Lung · China3RecruitingDec 2026318
NCT03941340Healthy Male Volunteers · China1CompletedSep 6, 20196
NCT03926182Healthy Male Volunteers · China1CompletedApr 3, 201916
NCT03452592Advanced NSCLC Patients With T790M · China2TerminatedApr 21, 2021220
NCT03127449Advanced NSCLC · China–TerminatedMay 12, 2021116
NCT02973763NSCLC1TerminatedFeb 4, 202114

How it is read

Names in the registry

  • “Furmonertinib”, 6 entries
  • “Alflutinib”, 3 entries
  • “ASK120067”, 3 entries
  • “Firmonertinib”, 2 entries
  • “Furmonertinib 160mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.